Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: GlaxoSmithKline vs. Bristol Myers Squibb

By Keith Speights - Apr 18, 2020 at 6:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two big drugmakers. One clear winner for investors.

If you're hunting for great stocks to buy while the market is still down, you'll definitely want to check out big pharma stocks. Many large drugmakers have strong financial positions. Nearly all of them market products that people will need, regardless of what happens at the macroeconomic level.

GlaxoSmithKline (GSK -0.17%) and Bristol Myers Squibb (BMY -0.55%) rank as two of the biggest pharmaceutical companies in the world. Both stocks are also down from their highs set earlier this year by double-digit percentages. Which pharma stock is the better buy? Here's how GSK and BMS compare.

Female scientist holding two test tubes

Image source: Getty Images.

The case for GlaxoSmithKline

GlaxoSmithKline is a company in transition. Over the short run, this transition is likely to be choppy. For example, GSK expects to post a net loss in 2020 as it prepares to split into two companies, one focused on consumer health and the other on pharmaceuticals and vaccines. But over the long term, GSK could be positioned for success.

The company claims several relatively new drugs on the market that should drive growth for years to come. Sales for respiratory drug Trelegy Ellipta are skyrocketing. HIV drugs Juluca and Dovato are picking up tremendous momentum. Ovarian cancer drug Zejula is another rising star.

GSK's vaccines business is especially strong. Shingles vaccine Shingrix is racking up monster sales, while the company's meningitis vaccines Bexsero and Menveo continue to perform well. It's a similar story for some of the older vaccines, including immunization booster Boostrix and pneumococcal vaccine Synflorix.

Sure, GlaxoSmithKline has some weak spots. The most glaring of these is respiratory drug Advair, with sales continuing to sink due to loss of exclusivity. However, the drag on GSK's year-over-year comparisons will diminish over time.

The company's pipeline includes several promising candidates. GSK awaits U.S. regulatory approvals for eight programs and also claims 10 late-stage programs, notably including rheumatoid arthritis drug otilimab and cabotegravir for HIV pre-exposure prophylaxis (PrEP).

While investors wait for GSK's transition period to wind down, they can enjoy a juicy dividend, which currently yields 5.4%. And while there have been some worries in the past that GSK might cut its dividend, those concerns appear to have largely subsided.

The case for Bristol Myers Squibb

Bristol Myers Squibb is undergoing a transition of its own. The big drugmaker acquired Celgene in November 2019, and the buyout has transformed BMS in a couple of significant ways.

Thanks to the Celgene acquisition, BMS now has blockbuster blood cancer drugs Revlimid and Pomalyst in its lineup, along with solid tumor drug Abraxane. These additions supplement BMS' already strong portfolio, which includes blood thinner Eliquis, cancer immunotherapy Opdivo, and immunology drug Orencia.

Celgene also brought several new drugs to the table that should be big winners in the future. Reblozyl won Food and Drug Administration (FDA) approval for treating anemia in patients with rare blood disease beta-thalassemia before BMS' buyout of the biotech closed. Subsequent to the deal wrapping up, the FDA approved Zeposia for treating relapsed multiple sclerosis. 

Bristol Myers Squibb does have a few challenges. Sales continue to fall for several of its older drugs that have lost exclusivity. Myelofibrosis drug Inrebic, which was developed by Celgene, is also off to a slow start after winning FDA approval in August 2019.

On the other hand, BMS' pipeline appears to be quite strong. The company has multiple late-stage clinical studies underway evaluating Opdivo either as a monotherapy or in combination with Yervoy in treating various types of cancer. It also claims a couple of promising cell therapies, ide-cel and liso-cel, both of which could generate blockbuster sales if approved.

BMS is no slouch in the dividend department, either. Its dividend yield currently stands at 3%. Considering BMS' strong earnings growth prospects, investors should be able to count on the dividend payout growing in the future.

Better buy

The decision between these two pharma stocks is an easy one. I think that Bristol Myers Squibb is the hands-down winner.

BMS has a stronger product lineup and a more promising pipeline than GlaxoSmithKline and has fewer problem areas. It's also more attractively priced than GSK, with shares trading at only 9.4 times expected earnings. My take is that Bristol Myers Squibb ranks as one of the top big pharma stocks to buy right now.

Keith Speights owns shares of Bristol Myers Squibb. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$74.15 (-0.55%) $0.41
GSK Stock Quote
GSK
GSK
$34.25 (-0.17%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.